Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01218802 (Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.Annals of internal medicine · 2025Guideline
- A Systematic Review and Meta-Analysis on the Impact of Statin Treatment in HIV Patients on Antiretroviral Therapy.International journal of environmental research and public health · 2023Pooled it
- Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.Annals of internal medicine · 2024Trial
- Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Trial
- Effect of Pericardial Fat Volume and Density on Markers of Insulin Resistance and Inflammation in Patients With Human Immunodeficiency Virus Infection.The American journal of cardiology · 2017Trial
- Baseline Vitamin D Deficiency Decreases the Effectiveness of Statins in HIV-Infected Adults on Antiretroviral Therapy.Journal of acquired immune deficiency syndromes (1999) · 2017Trial
- Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.AIDS (London, England) · 2017Trial
- Pathogenesis of HIV-Associated Metabolic Syndrome and Clinical Management Recommendations.International journal of general medicine · 2025Review
- A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system.Frontiers in pharmacology · 2024Article
- Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.Frontiers in immunology · 2024Review
- Statin initiation and risk of incident kidney disease in patients with diabetes.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.Current opinion in HIV and AIDS · 2022Review
- Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.Circulation · 2019Review
- Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.Current HIV/AIDS reports · 2018Review
- Benefits and Risks of Statin Therapy in the HIV-Infected Population.Current infectious disease reports · 2018Review
- Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases · 2017Review
- Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients.BMC infectious diseases · 2017 · on this mapObservational
- Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.Current HIV/AIDS reports · 2016Review
- Statins to improve cardiovascular outcomes in treated HIV infection.Current opinion in infectious diseases · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundStatins are associated with increased diabetes risk in large, human immunodeficiency virus (HIV)-uninfected cohorts; the impact of statins on insulin resistance or diabetes in HIV-infected persons has not been assessed within a randomized controlled study.
methodsHIV-infected participants on stable antiretroviral therapy with a low-density lipoprotein cholesterol level of ≤130 mg/dL and heightened immune activation or inflammation were randomized to rosuvastatin 10 mg daily or placebo for 96 weeks. Fasting serum glucose, insulin, and hemoglobin A1C (HgbA1C) were measured; insulin resistance was estimated by calculating the homeostatic model assessment of insulin resistance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered.
resultsSeventy-two participants were randomized to rosuvastatin therapy and 75 to placebo. Increases in fasting glucose were observed within both groups but were not different between study arms (P = .115); changes in glucose tolerance and HgbA1C did not differ between study arms (P = .920 and P = .650, respectively). Criteria for diabetes were met by 1 participant in the rosuvastatin and 3 in the placebo arm by week 96. Compared with placebo, rosuvastatin therapy was associated with significantly greater increases in insulin and HOMA-IR (P = .008 and P = .004, respectively).
conclusionsWe detected a significant worsening in insulin resistance and an increase in the proportion of participants with impaired fasting glucose but not a clinical diagnosis of diabetes in the rosuvastatin arm. Our findings suggest that prescription of statin therapy should be accompanied by a careful consideration of the risks and benefits, particularly in patients with lower cardiovascular disease risk. CLINICAL TRIALS REGISTRATION: NCT01218802.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.